;PMID: 11455201
;source_file_822.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..38] = [t:0..38]
;1)sentence:[e:44..204] = [t:44..204]
;2)section:[e:208..263] = [t:208..263]
;3)section:[e:267..368] = [t:267..368]
;4)sentence:[e:372..598] = [t:372..598]
;5)sentence:[e:599..828] = [t:599..828]
;6)sentence:[e:829..1026] = [t:829..1026]
;7)sentence:[e:1027..1174] = [t:1027..1174]
;8)sentence:[e:1175..1525] = [t:1175..1525]
;9)sentence:[e:1526..1692] = [t:1526..1692]
;10)sentence:[e:1693..2010] = [t:1693..2010]
;11)section:[e:2011..2045] = [t:2011..2045]
;12)section:[e:2049..2094] = [t:2049..2094]
;Token/POS Errors
;ERROR_Token in entity file but not tree[1547..1551] 6(Z)
;ERROR_Token in entity file but not tree[1551..1552] ,
;ERROR_Token in entity file but not tree[1552..1557] 15(Z)
;ERROR_Token in entity file but not tree[1557..1558] -
;ERROR_Token in entity file but not tree[1558..1560] 20
;ERROR_Token in entity file but not tree[1560..1561] -
;ERROR_Token in entity file but not tree[1561..1565] HEDE
;ERROR_Token in tree file but not entity[1547..1565] 6(Z),15(Z)-20-HEDE

;section 0 Span:0..38
;J Vasc Res. 2001 Jul-Aug;38(4):305-14.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..6] Vasc) (NNP:[7..10] Res) (.:[10..11] .)
        (CD:[12..16] 2001) (NNP:[17..20] Jul) (HYPH:[20..21] -)
        (JJ:[21..28] Aug;38-LRB-) (HYPH:[28..30] 4-RRB-) (CD:[30..34] :305)
        (HYPH:[34..35] -) (CD:[35..37] 14) (.:[37..38] .)))

;sentence 1 Span:44..204
;Relative contributions of cyclooxygenase- and cytochrome P450 
;omega-hydroxylase-dependent pathways to hypoxic dilation of skeletal muscle 
;resistance arteries.
;[70..84]:substance:"cyclooxygenase"
;[90..124]:substance:"cytochrome P450  omega-hydroxylase"
(SENT
  (NP-HLN
    (NP (JJ:[44..52] Relative) (NNS:[53..66] contributions))
    (PP (IN:[67..69] of)
      (NP
        (NP
          (ADJP (NN:[70..84] cyclooxygenase) (HYPH:[84..85] -)
            (ADJP-1 (-NONE-:[85..85] *P*)))
          (NML-2 (-NONE-:[85..85] *P*)))
        (CC:[86..89] and)
        (NP
          (ADJP
            (NML
              (NML (NN:[90..100] cytochrome) (NN:[101..105] P450))
              (NN:[107..124] omega-hydroxylase))
            (HYPH:[124..125] -)
            (ADJP-1 (JJ:[125..134] dependent)))
          (NML-2 (NNS:[135..143] pathways)))))
    (PP (TO:[144..146] to)
      (NP
        (NP (JJ:[147..154] hypoxic) (NN:[155..163] dilation))
        (PP (IN:[164..166] of)
          (NP
            (NML (JJ:[167..175] skeletal) (NN:[176..182] muscle))
            (NN:[184..194] resistance) (NNS:[195..203] arteries)))))
    (.:[203..204] .)))

;section 2 Span:208..263
;Frisbee JC, Roman RJ, Krishna UM, Falck JR, Lombard JH.
(SEC
  (FRAG (NNP:[208..215] Frisbee) (NNP:[216..218] JC) (,:[218..219] ,)
        (NNP:[220..225] Roman) (NNP:[226..228] RJ) (,:[228..229] ,)
        (NNP:[230..237] Krishna) (NNP:[238..240] UM) (,:[240..241] ,)
        (NNP:[242..247] Falck) (NNP:[248..250] JR) (,:[250..251] ,)
        (NNP:[252..259] Lombard) (NNP:[260..263] JH.)))

;section 3 Span:267..368
;Department of Physiology, Medical College of Wisconsin, Milwaukee, Wisc
;53226,  USA. jfrisbee@mcw.edu
(SEC
  (FRAG (NNP:[267..277] Department) (IN:[278..280] of)
        (NNP:[281..291] Physiology) (NNP:[291..292] ,) (NNP:[293..300] Medical)
        (NNP:[301..308] College) (IN:[309..311] of) (NNP:[312..321] Wisconsin)
        (,:[321..322] ,) (NNP:[323..332] Milwaukee) (,:[332..333] ,)
        (NNP:[334..338] Wisc) (CD:[339..344] 53226) (,:[344..345] ,)
        (NNP:[347..350] USA) (.:[350..351] .) ('':[352..364] jfrisbee@mcw)
        (.:[364..368] .edu)))

;sentence 4 Span:372..598
;This study determined the contribution of prostanoids, cytochrome P450
;(CP450)  4A enzyme metabolites of arachidonic acid, and other potential
;mediators of  hypoxic dilation of isolated rat skeletal muscle resistance
;arteries.
;[414..425]:substance:"prostanoids"
;[427..473]:substance:"cytochrome P450 (CP450)  4A enzyme metabolites"
;[477..493]:substance:"arachidonic acid"
;[515..524]:substance:"mediators"
(SENT
  (S
    (NP-SBJ (DT:[372..376] This) (NN:[377..382] study))
    (VP (VBD:[383..393] determined)
      (NP
        (NP (DT:[394..397] the) (NN:[398..410] contribution))
        (PP (IN:[411..413] of)
          (NP
            (NP (NNS:[414..425] prostanoids))
            (,:[425..426] ,)
            (NP
              (NP
                (NML
                  (NML
                    (NML (NN:[427..437] cytochrome) (NN:[438..442] P450))
                    (NML (-LRB-:[443..444] -LRB-) (NN:[444..449] CP450)
                         (-RRB-:[449..450] -RRB-)))
                  (NN:[452..454] 4A))
                (NN:[455..461] enzyme) (NNS:[462..473] metabolites))
              (PP (IN:[474..476] of)
                (NP (JJ:[477..488] arachidonic) (NN:[489..493] acid))))
            (,:[493..494] ,) (CC:[495..498] and)
            (NP
              (NP (JJ:[499..504] other) (JJ:[505..514] potential)
                  (NNS:[515..524] mediators))
              (PP (IN:[525..527] of)
                (NP
                  (NP (JJ:[529..536] hypoxic) (NN:[537..545] dilation))
                  (PP (IN:[546..548] of)
                    (NP (VBN:[549..557] isolated) (NN:[558..561] rat)
                      (NML (JJ:[562..570] skeletal) (NN:[571..577] muscle))
                      (NN:[578..588] resistance) (NNS:[589..597] arteries))))))))))
    (.:[597..598] .)))

;sentence 5 Span:599..828
;Gracilis  arteries (GA) were viewed via television microscopy and dilator
;responses to  hypoxia (reduction in superfusate and perfusate PO2 from
;approximately 145 to  approximately 40 mm Hg) were measured with a video
;micrometer.
;[758..761]:quantitative-value:"145"
;[780..782]:quantitative-value:"40"
;[783..788]:quantitative-units:"mm Hg"
(SENT
  (S
    (S
      (NP-SBJ-1
        (NP (NN:[599..607] Gracilis) (NNS:[609..617] arteries))
        (NP (-LRB-:[618..619] -LRB-) (NN:[619..621] GA) (-RRB-:[621..622] -RRB-)))
      (VP (VBD:[623..627] were)
        (VP (VBN:[628..634] viewed)
          (NP-1 (-NONE-:[634..634] *))
          (PP-MNR (IN:[635..638] via)
            (NP (NN:[639..649] television) (NN:[650..660] microscopy))))))
    (CC:[661..664] and)
    (S
      (NP-SBJ-5
        (NP (NN:[665..672] dilator) (NNS:[673..682] responses))
        (PP (TO:[683..685] to)
          (NP (NN:[687..694] hypoxia)))
        (PRN (-LRB-:[695..696] -LRB-)
          (NP
            (NP (NN:[696..705] reduction))
            (PP (IN:[706..708] in)
              (NP
                (NP (NN:[709..720] superfusate)
                  (NML-2 (-NONE-:[720..720] *P*)))
                (CC:[721..724] and)
                (NP (NN:[725..734] perfusate)
                  (NML-2 (NN:[735..738] PO2)))))
            (PP
              (PP (IN:[739..743] from)
                (NP
                  (NML
                    (ADVP (RB:[744..757] approximately) (CD:[758..761] 145))
                    (NML-3 (-NONE-:[761..761] *P*)))
                  (NML-4 (-NONE-:[761..761] *P*))))
              (PP (TO:[762..764] to)
                (NP
                  (NML
                    (QP (RB:[766..779] approximately) (CD:[780..782] 40))
                    (NML-3 (NN:[783..785] mm)))
                  (NML-4 (NN:[786..788] Hg))))))
          (-RRB-:[788..789] -RRB-)))
      (VP (VBD:[790..794] were)
        (VP (VBN:[795..803] measured)
          (NP-5 (-NONE-:[803..803] *))
          (PP-MNR (IN:[804..808] with)
            (NP (DT:[809..810] a) (NN:[811..816] video)
                (NN:[817..827] micrometer))))))
    (.:[827..828] .)))

;sentence 6 Span:829..1026
;Hypoxic dilation  of gracilis arteries was severely impaired by either
;endothelium removal or  cyclooxygenase inhibition with indomethacin, but not
;by nitric oxide synthase  inhibition with L-NAME.
;[924..938]:substance:"cyclooxygenase"
;[955..967]:substance:"indomethacin"
;[980..1001]:substance:"nitric oxide synthase"
;[1019..1025]:substance:"L-NAME"
(SENT
  (S
    (NP-SBJ-2
      (NP (JJ:[829..836] Hypoxic) (NN:[837..845] dilation))
      (PP (IN:[847..849] of)
        (NP (NN:[850..858] gracilis) (NNS:[859..867] arteries))))
    (VP
      (VP (VBD:[868..871] was)
        (ADVP (RB:[872..880] severely))
        (VP (VBN:[881..889] impaired)
          (NP-2 (-NONE-:[889..889] *))
          (PP=1 (IN:[890..892] by)
            (NP-LGS (CC:[893..899] either)
              (NP (NN:[900..911] endothelium) (NN:[912..919] removal))
              (CC:[920..922] or)
              (NP
                (NP (NN:[924..938] cyclooxygenase) (NN:[939..949] inhibition))
                (PP (IN:[950..954] with)
                  (NP (NN:[955..967] indomethacin))))))))
      (,:[967..968] ,) (CC:[969..972] but)
      (VP (RB:[973..976] not)
        (PP=1 (IN:[977..979] by)
          (NP-LGS
            (NML
              (NML
                (NML (JJ:[980..986] nitric) (NN:[987..992] oxide))
                (NN:[993..1001] synthase))
              (NN:[1003..1013] inhibition))
            (PP (IN:[1014..1018] with)
              (NP (NN:[1019..1025] L-NAME)))))))
    (.:[1025..1026] .)))

;sentence 7 Span:1027..1174
;Treatment of GA with 17-octadecynoic acid (17-ODYA)  alone to inhibit CP450
;4A enzymes significantly reduced hypoxic dilation from  control levels.
;[1048..1068]:substance:"17-octadecynoic acid"
;[1070..1077]:substance:"17-ODYA"
;[1097..1113]:cyp450:"CP450 4A enzymes"
(SENT
  (S
    (NP-SBJ
      (NP
        (NP (NN:[1027..1036] Treatment))
        (PP (IN:[1037..1039] of)
          (NP (NN:[1040..1042] GA)))
        (PP (IN:[1043..1047] with)
          (NP
            (NML
              (NML (JJ:[1048..1063] 17-octadecynoic) (NN:[1064..1068] acid))
              (NML (-LRB-:[1069..1070] -LRB-) (NN:[1070..1077] 17-ODYA)
                   (-RRB-:[1077..1078] -RRB-)))
            (ADVP (RB:[1080..1085] alone)))))
      (SBAR
        (WHNP-1 (-NONE-:[1085..1085] 0))
        (S
          (NP-SBJ-1 (-NONE-:[1085..1085] *ICH*))
          (VP (TO:[1086..1088] to)
            (VP (VB:[1089..1096] inhibit)
              (NP
                (NML (NN:[1097..1102] CP450) (NN:[1103..1105] 4A))
                (NNS:[1106..1113] enzymes)))))))
    (ADVP (RB:[1114..1127] significantly))
    (VP (VBD:[1128..1135] reduced)
      (NP (JJ:[1136..1143] hypoxic) (NN:[1144..1152] dilation))
      (PP (IN:[1153..1157] from)
        (NP (NN:[1159..1166] control) (NNS:[1167..1173] levels))))
    (.:[1173..1174] .)))

;sentence 8 Span:1175..1525
;Treatment of vessels with  N-methylsulfonyl-6-(2-proparglyoxyphenyl)hexanoic
;acid (MS-PPOH) to inhibit the  production of epoxyeicosatrienoic acids (EETs)
;did not alter hypoxic dilation,  although treatment with
;dibromo-dodecenyl-methylsulfimide (DDMS) to inhibit 
;20-hydroxyeicosatetraenoic acid (20-HETE) production had similar effects as 
;17-ODYA.
;[1202..1256]:substance:"N-methylsulfonyl-6-(2-proparglyoxyphenyl)hexanoic
;acid"
;[1258..1265]:substance:"MS-PPOH"
;[1297..1322]:substance:"epoxyeicosatrienoic acids"
;[1324..1328]:substance:"EETs"
;[1387..1420]:substance:"dibromo-dodecenyl-methylsulfimide"
;[1422..1426]:substance:"DDMS"
;[1440..1471]:substance:"20-hydroxyeicosatetraenoic acid"
;[1473..1480]:substance:"20-HETE"
;[1517..1524]:substance:"17-ODYA"
(SENT
  (S
    (NP-SBJ
      (NP
        (NP (NN:[1175..1184] Treatment))
        (PP (IN:[1185..1187] of)
          (NP (NNS:[1188..1195] vessels)))
        (PP (IN:[1196..1200] with)
          (NP
            (NP
                (JJ:[1202..1251] N-methylsulfonyl-6--LRB-2-proparglyoxyphenyl-RRB-hexanoic)
                (NN:[1252..1256] acid))
            (NP (-LRB-:[1257..1258] -LRB-) (NN:[1258..1265] MS-PPOH)
                (-RRB-:[1265..1266] -RRB-)))))
      (SBAR
        (WHNP-1 (-NONE-:[1266..1266] 0))
        (S
          (NP-SBJ-1 (-NONE-:[1266..1266] *T*))
          (VP (TO:[1267..1269] to)
            (VP (VB:[1270..1277] inhibit)
              (NP
                (NP (DT:[1278..1281] the) (NN:[1283..1293] production))
                (PP (IN:[1294..1296] of)
                  (NP
                    (NP (JJ:[1297..1316] epoxyeicosatrienoic)
                        (NNS:[1317..1322] acids))
                    (NP (-LRB-:[1323..1324] -LRB-) (NNS:[1324..1328] EETs)
                        (-RRB-:[1328..1329] -RRB-))))))))))
    (VP (VBD:[1330..1333] did) (RB:[1334..1337] not)
      (VP (VB:[1338..1343] alter)
        (NP (JJ:[1344..1351] hypoxic) (NN:[1352..1360] dilation))
        (,:[1360..1361] ,)
        (SBAR-ADV (IN:[1363..1371] although)
          (S
            (NP-SBJ
              (NP
                (NP (NN:[1372..1381] treatment))
                (PP (IN:[1382..1386] with)
                  (NP
                    (NP (NN:[1387..1420] dibromo-dodecenyl-methylsulfimide))
                    (NP (-LRB-:[1421..1422] -LRB-) (NN:[1422..1426] DDMS)
                        (-RRB-:[1426..1427] -RRB-)))))
              (SBAR
                (WHNP-2 (-NONE-:[1427..1427] 0))
                (S
                  (NP-SBJ-2 (-NONE-:[1427..1427] *T*))
                  (VP (TO:[1428..1430] to)
                    (VP (VB:[1431..1438] inhibit)
                      (NP
                        (NML
                          (NML (JJ:[1440..1466] 20-hydroxyeicosatetraenoic)
                               (NN:[1467..1471] acid))
                          (NML (-LRB-:[1472..1473] -LRB-)
                               (NN:[1473..1480] 20-HETE)
                               (-RRB-:[1480..1481] -RRB-)))
                        (NN:[1482..1492] production)))))))
            (VP (VBD:[1493..1496] had)
              (NP
                (NP (JJ:[1497..1504] similar) (NNS:[1505..1512] effects))
                (PP (IN:[1513..1515] as)
                  (NP (NN:[1517..1524] 17-ODYA)))))))))
    (.:[1524..1525] .)))

;sentence 9 Span:1526..1692
;Treatment of GA with 6(Z),15(Z)-20-HEDE, a competitive antagonist of  the
;actions of 20-HETE, mimicked the effects of 17-ODYA and DDMS treatment on 
;hypoxic dilation.
;[1547..1565]:substance:"6(Z),15(Z)-20-HEDE"
;[1581..1591]:substance:"antagonist"
;[1611..1618]:substance:"20-HETE"
;[1644..1651]:substance:"17-ODYA"
;[1656..1660]:substance:"DDMS"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1526..1535] Treatment))
      (PP (IN:[1536..1538] of)
        (NP (NN:[1539..1541] GA)))
      (PP (IN:[1542..1546] with)
        (NP
          (NP (NN:[1547..1565] 6-LRB-Z-RRB-,15-LRB-Z-RRB--20-HEDE))
          (,:[1565..1566] ,)
          (NP
            (NP (DT:[1567..1568] a) (JJ:[1569..1580] competitive)
                (NN:[1581..1591] antagonist))
            (PP (IN:[1592..1594] of)
              (NP
                (NP (DT:[1596..1599] the) (NNS:[1600..1607] actions))
                (PP (IN:[1608..1610] of)
                  (NP (NN:[1611..1618] 20-HETE)))))))))
    (,:[1618..1619] ,)
    (VP (VBD:[1620..1628] mimicked)
      (NP
        (NP (DT:[1629..1632] the) (NNS:[1633..1640] effects))
        (PP (IN:[1641..1643] of)
          (NP
            (NP (NN:[1644..1651] 17-ODYA)
              (NML-1 (-NONE-:[1651..1651] *P*)))
            (CC:[1652..1655] and)
            (NP (NN:[1656..1660] DDMS)
              (NML-1 (NN:[1661..1670] treatment)))))
        (PP (IN:[1671..1673] on)
          (NP (JJ:[1675..1682] hypoxic) (NN:[1683..1691] dilation)))))
    (.:[1691..1692] .)))

;sentence 10 Span:1693..2010
;These results suggest that hypoxic dilation of skeletal muscle  resistance
;arteries primarily represents the effects of enhanced prostanoid  release
;from vascular endothelium, although a contribution of reduced 20-HETE 
;production via CP450 omega-hydroxylase enzymes also regulates hypoxic
;dilation  of these vessels.
;[1822..1832]:substance:"prostanoid"
;[1904..1911]:substance:"20-HETE"
;[1928..1959]:substance:"CP450 omega-hydroxylase enzymes"
(SENT
  (S
    (NP-SBJ (DT:[1693..1698] These) (NNS:[1699..1706] results))
    (VP (VBP:[1707..1714] suggest)
      (SBAR (IN:[1715..1719] that)
        (S
          (NP-SBJ
            (NP (JJ:[1720..1727] hypoxic) (NN:[1728..1736] dilation))
            (PP (IN:[1737..1739] of)
              (NP
                (NML (JJ:[1740..1748] skeletal) (NN:[1749..1755] muscle))
                (NN:[1757..1767] resistance) (NNS:[1768..1776] arteries))))
          (ADVP (RB:[1777..1786] primarily))
          (VP (VBZ:[1787..1797] represents)
            (NP
              (NP (DT:[1798..1801] the) (NNS:[1802..1809] effects))
              (PP (IN:[1810..1812] of)
                (NP (VBN:[1813..1821] enhanced) (NN:[1822..1832] prostanoid)
                    (NN:[1834..1841] release)))
              (PP (IN:[1842..1846] from)
                (NP (JJ:[1847..1855] vascular) (NN:[1856..1867] endothelium))))
            (,:[1867..1868] ,)
            (SBAR-ADV (IN:[1869..1877] although)
              (S
                (NP-SBJ
                  (NP (DT:[1878..1879] a) (NN:[1880..1892] contribution))
                  (PP (IN:[1893..1895] of)
                    (NP (VBN:[1896..1903] reduced) (NN:[1904..1911] 20-HETE)
                        (NN:[1913..1923] production)))
                  (PP (IN:[1924..1927] via)
                    (NP (NN:[1928..1933] CP450)
                        (NN:[1934..1951] omega-hydroxylase)
                        (NNS:[1952..1959] enzymes))))
                (ADVP (RB:[1960..1964] also))
                (VP (VBZ:[1965..1974] regulates)
                  (NP
                    (NP (JJ:[1975..1982] hypoxic) (NN:[1983..1991] dilation))
                    (PP (IN:[1993..1995] of)
                      (NP (DT:[1996..2001] these) (NNS:[2002..2009] vessels)))))))))))
    (.:[2009..2010] .)))

;section 11 Span:2011..2045
;Copyright 2001 S. Karger AG, Basel
(SEC
  (FRAG (NN:[2011..2020] Copyright) (CD:[2021..2025] 2001) (NNP:[2026..2028] S.)
        (NNP:[2029..2035] Karger) (NNP:[2036..2038] AG) (,:[2038..2039] ,)
        (NNP:[2040..2045] Basel)))

;section 12 Span:2049..2094
;PMID: 11455201 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2049..2053] PMID) (::[2053..2054] :) (CD:[2055..2063] 11455201)
        (IN:[2064..2065] -LSB-) (NNP:[2065..2071] PubMed) (HYPH:[2072..2073] -)
        (JJ:[2074..2081] indexed) (IN:[2082..2085] for)
        (NNP:[2086..2094] MEDLINE-RSB-)))
